0.00Open0.00Pre Close0 Volume0 Open Interest13.00Strike Price0.00Turnover249.90%IV-72.64%PremiumDec 20, 2024Expiry Date5.47Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9570Delta0.0428Gamma1.37Leverage Ratio-0.0163Theta-0.0012Rho-1.31Eff Leverage0.0008Vega
BioCryst Pharmaceuticals Stock Discussion
BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.81%)
Larger Image: tradingview.com...
$BioCryst Pharmaceuticals (BCRX.US)$
Benzinga· 3 mins ago
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reduc...
Just
U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile
Jefferies analysts cited 10 possible policies that Tr...
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
No comment yet